These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2011-004074-28||A prospective, open label, multicenter, partially randomized, safety study of one cycle of Promethera HepaStem in Urea Cycle Disorders and Crigler-Najjar Syndrome Patients||2014-11-04||due-trials|
|Not reported||2013-001045-14||SAF 001: A long-term safety follow-up study of patients having received infusions of HepaStem.||2017-07-20||due-trials|
|Ongoing||2014-000650-11||A prospective, open label, multicenter, efficacy and safety study of several infusions of Promethera HepaStem in Urea Cycle Disorders pediatric patients||not-yet-due|
|Trial is outside EEC, and reported results||2015-000988-14||Title: Open, Prospective, Historic-Controlled, Multicenter Study to||bad-data|
|Ongoing||2016-001177-32||Multicenter Phase II Safety and Preliminary Efficacy Study of 2 dose regimens of HepaStem in Patients with Acute on Chronic Liver Failure||not-yet-due|
|Other||2017-003989-27||HepaStem Long-Term Safety Registry : Registry for patients who have been administered HepaStem||not-yet-due|
|Ongoing||2018-004449-18||Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH).||not-yet-due|
|Ongoing||2019-003051-11||Randomized, placebo-controlled, double blind, multi-centre Phase IIb study to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) - DHELIVER||not-yet-due|